ASP Isotopes (ASPI) Earnings Date & Reports

ASP Isotopes posted FY 2025 revenue of $23.8 million, up sharply from $4.1 million the prior year, with $18.2 million from construction services and $5.7 million in product revenue (up 46% YoY). Q4 revenue exploded to $16.7 million, a 1,295% YoY increase and well above expectations of approximately $2.6 million, fueled by project milestones.

Despite the top-line beat, profitability remained elusive. Q4 GAAP EPS was -$0.84, versus consensus of -$0.14, while full-year net loss expanded to $175.1 million or -$2.11 per share, driven by operating expenses and capex for enrichment facilities. Balance sheet strengthened with $333 million in cash, supporting ongoing projects. No specific 2026 guidance was provided, but management highlighted near-term commercial progress.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your research process.

Market Reaction and Investor Sentiment

ASPI shares rose about 19.6% in the days following the earnings release, reflecting optimism over the revenue trajectory and robust cash position despite the EPS miss. Premarket trading showed a 2.5% gain, with investors focusing on commercial milestones rather than near-term losses. Sentiment remains cautiously bullish, buoyed by the company's shift to revenue-generating operations in a niche, high-demand market.

Forward Outlook and Key Factors to Monitor

Following Q4 results, ASP Isotopes is poised for a year of commercialization in 2026. Management expects first shipments of multiple isotopes, including those for nuclear medicine and semiconductors, signaling the start of recurring revenue streams.

A key near-term catalyst is achieving Helium-3 Phase 1 nameplate capacity in Q3 2026, critical for quantum and medical applications. Investors should track progress on facility commissioning in South Africa and potential U.S. expansion, as delays could pressure the timeline.

Cash burn remains a focus, with $333 million providing runway but substantial capex ahead for Phase 2 projects estimated at over $1 billion long-term. Operating margins will depend on production efficiencies and customer contracts. Broader industry dynamics, such as nuclear energy demand and supply chain isotope shortages, could accelerate growth.

Upcoming Q1 2026 earnings in May will offer updates on these milestones. Monitor SEC filings for 10-Q details and any partnership announcements.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations